MASI - CIK 0000937556
MASIMO CORP trades as MASI and has a market capitalization of $9.43 B, making it the #972 largest US-listed company by market value. In its fiscal 2026 annual report the company posted revenue of $1.53B, up 9.4% from the prior year and net income of -$151.50M. This page tracks MASIMO CORP through 1,510 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 10 fiscal years MASIMO CORP's revenue grew from $712.90M to $1.53B, a compound annual growth rate of 7.9%. Net profit margin compressed from 43.6% to -9.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Major company event | 8-K | 2026-05-04 |
Katie Szyman, Chief Executive Officer of Masimo, stated: “We thank our shareholders for their strong support of this important milestone for Masimo. The Merger delivers compelling value and positions Masimo for continued global growth as an independent operating company within Danaher’s Diagnostics segment. We look forward to completing this process and, together with Danaher, continuing our mission of developing innovative technologies that empower clinicians to transform patient care.”
_NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns_
Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (“Danaher”) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the “Transaction”).
_Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)_
The largest companies sharing MASIMO CORP's SEC industry classification (electromedical & electrotherapeutic apparatus).
MASIMO CORP (MASI) has a market capitalization of $9.43 B as of 2026-06-10, ranking #972 among US-listed companies.
MASIMO CORP reported revenue of $1.53B for fiscal year 2026, an increase of 9.4% year over year.
In its latest fiscal year MASIMO CORP reported a net loss of $151.50M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
_Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026_